Drug Res (Stuttg) 2021; 71(06): 348-350
DOI: 10.1055/a-1467-5956
Short Communication

A Concept for the Reduction of Mucosal SARS-CoV-2 Load using Hypochloric Acid Solutions

Christian A. Mueller
1   Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria
Michael Winter
2   Team Winter Kompetenztraining, Vienna, Austria
Bertold Renner
3   Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
4   Institute of Clinical Pharmacology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
› Institutsangaben


During the next few months or years, vaccination against SARS-CoV-2 infection will significantly reduce the morbidity and mortality of COVID-19. However, additional measures are needed to protect those who are still not immunized. This is even more important in view of new viral mutations that result in increased transmission rates. We propose that the use of long-standing medicinal solutions based on hypochloric acid (HOCl) and intended for application on wounds may be effective as a gargling solution or nasal irrigation in blocking transmission of the virus. Here, we propose the use of HOCl-containing solutions for blocking the transmission of SARS-CoV-2 in combination with other prevention measures. This may constitute another important cornerstone in the fight against the COVID-19 pandemic.


Eingereicht: 07. März 2021

Angenommen: 22. März 2021

Artikel online veröffentlicht:
22. April 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

  • References

  • 1 World Health Organization, report Coronavirus disease (COVID-2019) situation reports. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports; accessed 31 January 2021
  • 2 Sahin U, Muik A, Derhovanessian E. et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature 2020; 586: 594-599
  • 3 Fontanet A, Cauchemez S. COVID-19 herd immunity: where are we?. Nat Rev Immunol 2020; 20: 583-584
  • 4 Wang D, Li Z, Liu Y. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. J Infect. Public Health 2020; 13: 1405-1414
  • 5 Tamaki S, Bui VN, Ngo LH. et al. Virucidal effect of acidic electrolyzed water and neutral electrolyzed water on avian influenza viruses. Arch Virol 2014; 159: 405-412
  • 6 Thorn RM, Lee SW, Robinson GM. et al. Electrochemically activated solutions: Evidence for antimicrobial efficacy and applications in healthcare environments. Eur J Clin Microbiol Infect Dis 2012; 31: 641-653
  • 7 Park GW, Boston DM, Kase JA. et al. Evaluation of liquid- and fog-based application of Sterilox hypochlorous acid solution for surface inactivation of human norovirus. Appl Environ Microbiol 2007; 73: 4463-4468
  • 8 Morita C, Sano K, Morimatsu S. et al. Disinfection potential of electrolyzed solutions containing sodium chloride at low concentrations. J Virol Methods 2000; 85: 163-174
  • 9 Takeda Y, Uchiumi H, Matsuda S. et al. Acidic electrolyzed water potently inactivates SARS-CoV-2 depending on the amount of free available chlorine contacting with the virus. Biochem Biophys Res Commun 2020; 530: 1-3
  • 10 Sarada BV, Vijay R, Johnson RT. et al. Fight Against COVID-19: ARCI’s Technologies for Disinfection. Trans Indian Natl Acad Eng 2020; 5: 349-354
  • 11 Huang JT, Abrams M, Tlougan B. et al. Treatment of Staphylococcus aureus Colonization in Atopic Dermatitis Decreases Disease Severity. Pediatrics 2009; 123: e808-e814
  • 12 Cho HJ, Min HJ, Chung HJ. et al. Improved outcomes after low-concentration hypochlorous acid nasal irrigation in pediatric chronic sinusitis. Laryngoscope 2016; 126: 791-795
  • 13 Wang L, Bassiri M, Najafi R. et al. Hypochlorous acid as a potential wound care agent: part I. Stabilized hypochlorous acid: a component of the inorganic armamentarium of innate immunity. J Burns Wounds 2007; (11) 6: e5
  • 14 Renner B, Mueller CA, Shephard A. Environmental and non-infectious factors in the aetiology of pharyngitis (sore throat). Inflamm Res 2012; 61: 1041-1052
  • 15 de Vries RD, Schmitz KS, Bovier FT. et al. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science 2021; Feb 17 eabf4896